Catheter-related Bloodstream Infections

Catheter-related bloodstream infections (CRBSIs) are preventable healthcare-associated infections linked to intravascular catheters, particularly central venous catheters. They can cause sepsis, prolonged hospitalization, higher treatment complexity, and avoidable mortality. Prevention depends on consistent insertion, maintenance, surveillance, and rapid response practices across acute-care and other clinical settings.

The field is moving toward bundled prevention, standardized insertion checklists, chlorhexidine-based skin antisepsis where clinically appropriate, sterile barrier precautions, optimized catheter-site selection, and prompt removal of unnecessary devices. Increasing attention is also being placed on maintenance reliability, staff competency, hand hygiene, dressing integrity, hub disinfection, and organizational safety culture. Measurement is evolving from isolated infection counts toward process compliance, unit-level feedback, and investigation of local causes.

Artificial intelligence can support CRBSI prevention by integrating electronic health records, microbiology results, device data, nursing documentation, and laboratory trends. Potential applications include earlier identification of suspected infections, detection of missed maintenance steps, risk stratification, anomaly detection, and automated reporting. Clinical validation, transparent decision logic, cybersecurity, data quality controls, and human oversight remain essential because false alerts, incomplete documentation, and confounding by patient acuity can undermine performance.

North America generally benefits from mature infection-prevention programs, established surveillance, and extensive quality-improvement infrastructure, while Latin America continues to address variation in staffing, laboratory capacity, and implementation consistency. Europe combines strong clinical guidance with differing national reporting systems and resource environments. The Middle East includes highly developed hospital networks alongside settings where specialized infection-control capacity is less consistent. Africa faces major challenges involving access to supplies, staffing, microbiology, and surveillance, although targeted quality initiatives can produce meaningful gains. Asia-Pacific is diverse, with advanced systems in some jurisdictions and substantial infrastructure and workforce variation in others.

ASEAN members may benefit from adaptable regional protocols, workforce training, and stronger cross-border learning while accounting for differing hospital capabilities. BRICS countries span highly varied healthcare systems, making locally calibrated surveillance and implementation support important. The European Union emphasizes coordinated patient-safety principles while retaining national and institutional differences in reporting. G7 health systems generally have substantial research and surveillance capacity, but persistent variation between facilities remains relevant. GCC countries can leverage concentrated hospital infrastructure and centralized quality programs, while NATO members may benefit from interoperable infection-control practices and preparedness-oriented clinical collaboration.

Australia and Canada emphasize standardized surveillance, stewardship, and safety-culture improvement. Brazil, Mexico, India, China, and Russia must address substantial variation across regions, facility types, staffing models, and laboratory access. France, Germany, Italy, Spain, and the United Kingdom can build on established infection-prevention systems while improving consistency, data comparability, and device-use governance. Japan and South Korea combine advanced hospital capabilities with opportunities to strengthen aging-population care pathways, documentation, and continuous monitoring. In the United States, sustained attention to bundle adherence, reporting quality, and variation between hospitals remains important.

Leaders should establish clear accountability for catheter necessity, insertion, and maintenance; standardize evidence-based bundles; audit practice at the point of care; and provide rapid, nonpunitive feedback. Investment should prioritize competency-based training, dependable supplies, microbiology access, device-removal prompts, and interoperable surveillance. Organizations should segment results by unit and patient context, investigate every suspected cluster, and pair technology adoption with clinician governance. AI initiatives should begin with narrowly defined use cases, prospective validation, bias monitoring, and explicit escalation pathways.

This executive summary synthesizes established clinical and public-health evidence on CRBSI definitions, risk factors, prevention bundles, surveillance, diagnostics, antimicrobial management, healthcare delivery, and digital tools. The analysis organizes findings across the specified regions, country groups, and countries, emphasizing differences in infrastructure, regulation, workforce, and implementation conditions. It excludes market sizing, financial estimates, market shares, forecasts, and company-specific analysis. Interpretations should be updated against current national guidance, local surveillance definitions, and facility-level data before operational decisions are made.

Reducing CRBSIs requires more than introducing a single product or protocol. Durable improvement comes from reliable device necessity assessment, technically correct insertion, disciplined maintenance, timely removal, robust surveillance, and learning-oriented leadership. Regional and national differences should shape implementation without weakening core safety principles. Carefully governed digital and AI tools can extend prevention capacity, but measurable clinical improvement will depend on workforce readiness, trustworthy data, and consistent execution at the bedside.